Low-dose oral anticoagulation in patients with mechanical heart valve prostheses: final report from the early self-management anticoagulation trial II
|
|
- Clifford Barber
- 6 years ago
- Views:
Transcription
1 European Heart Journal (2007) 28, doi: /eurheartj/ehm391 Clincial research Valvular heart disease Low-dose oral anticoagulation in patients with mechanical heart valve prostheses: final report from the early self-management anticoagulation trial II Heinrich Koertke 1 *, Armin Zittermann 1, Gero Tenderich 1, Otto Wagner 1, Mahmoud El-Arousy 1, Arno Krian 2, Juergen Ennker 3, Uwe Taborski 4, Wolf Peter Klövekorn 4, Rainer Moosdorf 5, Werner Saggau 6, and Reiner Koerfer 1 1 Department of Thoracic and Cardiovascular Surgery, Heart and Diabetes Center North Rhine-Westphalia Bad Oeynhausen, University Hospital of the Ruhr-University of Bochum, Georgstr , Bad Oeynhausen, Germany; 2 Evangelisches Johanniter Klinikum, Duisburg, Germany; 3 HeartCenter Lahr, Lahr, Germany; 4 Kerckhoff-Klinik, Bad Nauheim, Germany; 5 Heart Center Marburg, Clinic of the Philipps-University Marburg, Marburg, Germany; and 6 Klinikum Ludwigshafen, Clinic for Heart Surgery, Ludwigshafen, Germany Received 17 January 2007; revised 30 July 2007; accepted 23 August 2007; online publish-ahead-of-print 21 September 2007 See page 2424 for the editorial comment on this article (doi: /eurheartj/ehm405) KEYWORDS Oral anticoagulation; INR self-management; Heart valve prostheses; Thrombo-embolism; Bleeding Aims In mechanical heart valve recipients, low-dose international normalized ratio (INR) selfmanagement of oral anticoagulants can reduce the risk of developing thrombo-embolic events and improve long-term survival compared with INR control by a general practitioner. Here, we present data on the safety of low-dose INR self-management. Methods and results In a prospective, randomized multi-centre trial, 1346 patients with a target INR range of and 1327 patients with a target INR range of for aortic valve recipients and an INR range of for mitral or double valve recipients were followed up for 24 months. The incidence of thrombo-embolic events that required hospital admission was 0.37 and 0.19% per patient year in the conventional and low-dose groups, respectively (P¼0.79). No thrombo-embolic events occurred in the subgroups of patients with mitral or double valve replacement. The incidence of bleeding events that required hospital admission was 1.52 and 1.42%, respectively (P¼0.69). In the majority of patients with bleeding events, INR values were,3.0. Mortality rate did not differ between the study groups. Conclusion Data demonstrate that low-dose INR self-management does not increase the risk of thrombo-embolic events compared with conventional dose INR self-management. Even in patients with low INR target range, the risk of bleeding events is still higher than the risk of thrombo-embolism. Introduction Patients who undergo mechanical heart valve replacement require life-long oral anticoagulants. The Early Self-controlled Anticoagulation Trial (ESCAT) I demonstrated that selfmanagement of oral anticoagulants improves the percentage of international normalized ratio (INR) values within the target range, reduces thrombo-embolic events, and improves long-term survival compared with the management of oral anticoagulants by a general practitioner. 1,2 The ESCAT II study is a large prospective interventional trial that evaluates *Corresponding author. Tel: þ ; fax: þ address: hkoertke@hdz-nrw.de the effects of low-dose INR self-management on oral anticoagulants-related complications in patients with mechanical heart valve prostheses compared with conventional dose INR self-management. In a recently published interim analysis of the ESCAT II study, we found that the INR target range can be reduced from to in patients with aortic valve replacement and to in patients with mitral valve or double valve replacement, without increasing the risk of thrombo-embolic events. 3 In line with our findings, a target INR range of for aortic heart valve prostheses for patients without additional risk factors and a target INR range of for mitral heart valve prostheses have recently been recommended. 4 Our interim Published on behalf of the European Society of Cardiology. All rights reserved. & The Author For permissions please journals.permissions@oxfordjournals.org. The online version of this article has been published under an open access model. Users are entitled to use, reproduce, disseminate, or display the open access version of this article for non-commercial purposes provided that the original authorship is properly and fully attributed; the Journal, Learned Society and Oxford University Press are attributed as the original place of publication with correct citation details given; if an article is subsequently reproduced or disseminated not in its entirety but only in part or as a derivative work this must be clearly indicated. For commercial re-use, please contact journals.permissions@oxfordjournals.org.
2 2480 H. Koertke et al. analysis of the ESCAT II study also demonstrated that the percentage of clinically relevant bleeding events was approximately three- to four-fold higher than the percentage of clinically relevant thrombo-embolic events. 3 The relatively high number of bleeding events compared with the number of thrombo-embolic events in our study is in line with the results of an earlier investigation, demonstrating that a minimum risk of death was attained at 2.3 INR for patients with mechanical heart valve prostheses. 5 With an increase of 1 unit of INR.2.5, the risk of death from cerebral bleeding, as well as from other causes, was approximately doubled. The ESCAT II study has now been terminated. Here, we provide final data on thrombo-embolism and hemorrhage of the ESCAT II study and present a detailed evaluation of major thrombo-embolic and bleeding complications. Methods Patients In total, 2673 patients were included in the ESCAT II study. Mechanical aortic valve replacement was performed in 2164 patients, mitral valve replacement in 392 patients, tricuspid valve replacement in three patients, aortic plus mitral heart valve replacement in 113 patients, and a mitral plus tricuspid valve replacement in one patient. Exclusion criteria were: a contraindication to phenprocoumon (e.g. allergy), known ulcerous disease with bleeding tendency, hypo- or hypercoagulability (medical history), and an age of,18 years. All patients gave written informed consent to the study procedures. The study protocol was approved by the Ethics Committee of each of the six participating centres. Study design 1311 St. Jude Medical heart valves (St Jude Medical GmbH, Nuremberg, Germany), 1260 Medtronic Hall heart valves (Medtronic Hall, Medtronic GmbH, Dusseldorf, Germany), and 102 other heart valves from different manufacturers were implanted (38 Carbomedics heart valves, 35 ATS heart valves, eight Advantage heart valves, eight On-x heart valves, four Pyrolite heart valves, three Ultracor heart valves, two Mosaic heart valves, two Omni Carbon heart valves, and two Tissuemed heart valves). The conventional dose (CON) group (n ¼ 1346) had a target INR range of The low-dose (LOW) group (n ¼ 1327) had a target range of for aortic valve recipients and for mitral or double valve recipients. Study duration was from October 1998 to March The follow-up period was 24 months for each patient. The concept of INR self-management at our clinics is described in detail elsewhere. 3,6 Briefly, all study participants joined a training course for INR self-management. Each patient had to learn to determine the INR values and to correct the dose of anticoagulants autonomously. The participants of the ESCAT II study had to check their INR values once a week during the first study year and once a fortnight during the second study year. The results had to be submitted to the study centre every month. All patients had to visit their study centre for a cardiologic check-up every 6 months. Patients were asked to report any complication to the study centre immediately. Moreover, the patients were asked during their follow-up visits whether any complication had occurred within the last 6 months. All reports of grade III complications were sent from the emergency hospital to the study centre and were double-checked by a cardiologist of the centre. Finally, the study centre in Bad Oeynhausen contacted each local study centre regularly in order to get information about the number of bleeding and thrombo-embolism events. Only grade III complications were used for data analysis, as previously described. 7 Briefly, grade III thrombo-embolism was defined as heart valve prosthesis thrombosis or severe thrombo-embolism requiring inpatient treatment or causing long-term impairment (including transient ischaemic attacks). Grade III bleeding was defined as severe bleeding, requiring transfusion, surgical or endoscopic intervention, and inpatient care or causing long-term impairment. Moreover, each death and its cause was documented during follow-up. Statistics Statistical evaluations were performed with the program SPSS, version 11 (Chicago, IL, USA). For comparative evaluations, x 2 test and Student s t-test (normally distributed data) were used. Normal distribution of the data was tested using the Kolmogorov Smirnov test. Categorical variables were reported using the number (n) and percentage of observations. Continuous variables were expressed as mean (SD) and median and interquartile range (IQR) when appropriate. For comparative analyses of baseline characteristics, we used Fisher s exact test, the unpaired t-test, and the Mann Whitney U-test when appropriate. Kaplan Meier analyses were used to calculate freedom from grade III complications and survival rates. Differences in complication and survival rates between study groups were tested with the log-rank test. We used univariable and multivariable Cox proportional hazard analysis to examine the associations of different parameters, such as study group, age, left ventricular ejection fraction (LVEF), atrial fibrillation, diabetes mellitus and hypertension with freedom from thrombo-embolism or haemorrhage. P-value of,0.05 was considered statistically significant. Results Baseline characteristics of the two study groups are given in Table 1. The study groups did not differ with regard to age, sex, and several biochemical and clinical parameters. It was noteworthy that a significant percentage of patients in both study groups were hypertensive and required treatment with antihypertensive drugs. A total of 532 patients (19.9%) terminated the study prematurely. Reasons were: patient could not manage the device/no confidence in the device (n¼102), had more confidence in her/his physician (n¼92), measurements were stopped because of illness (n¼74), non-compliance of patients (n¼162), non-interest in INR self-management (n¼19), missed or incomplete instruction for INR selfmanagement (n¼45), device not paid by health insurance (n¼5), and too high travel costs to the place of re-examination (n¼7). Some even terminated with no comment (n¼26). The percentage of study dropouts in the low-dose INR and the conventional dose INR did not differ significantly (data not shown). Patients dropped out after a median study period of 7 months (IQR, 1 18 months). Until the patients dropped out, all INR values and complication data of these patients were considered for statistical analysis. In total, the 2673 patients accrued 4294 patient-years of observation. During the investigation period, the LOW and the CON groups submitted a total of and INR values to the study centre, respectively. In patients with aortic valve replacement, mean INR values were 2.40 (SD, 0.50) in the LOW group and 2.80 (0.59) in the CON group (P,0.001). In patients with mitral and double valve replacement, mean INR values were 2.90 (0.60) in the LOW group and 3.10 (0.67) in the CON group (P,0.001). The mean phenprocoumon doses in the CON group and in the LOW
3 Low-dose INR self-management 2481 Table 1 Characteristics of patients with low-dose INR self-management and with conventional dose INR self-management LOW group (n¼1327) CON group (n¼1346) Significance Age (years) NS Male (%) NS Weight (kg) NS Height (m) NS Smoker (%) NS Hypertension (%) NS Hypercholesterolemia (%) NS Atrial fibrillation (%) NS Diabetes mellitus NS Aspirin use (%) NS Left-ventricular ejection fraction (%).50% NS 30 50% NS,30% NS Red blood cells (10 12 L 21 ) NS Hemoglobin (g/dl) NS Hematocrit (%) NS Fibrinogen (mg/dl) NS Total cholesterol (mg/dl) NS HDL cholesterol (mg/dl) NS LDL cholesterol (mg/dl) NS Blood pressure, systolic (mmhg) NS Blood pressure, diastolic (mmhg) NS Heart rate (beats/min) NS LOW, low dose; CON, conventional dose; NS, not significant. group were 16.8 (6.9) and 15.9 (6.3) mg/week, respectively (P,0.001). Approximately 77% of the INR values measured in the LOW group and 75% of the INR values measured in the CON group were within the group-specific target range. We also evaluated the time spent within target range during the first, second, third, and fourth half-years. There were no significant time effects, neither in the CON group nor in the LOW group (data not shown). Moreover, the results did not differ between the aortic and the mitral or double valve (data not shown). In the LOW group, 7% of the INR values were below and 16% above the target range. The corresponding values for the CON group were 23 and 2%, respectively. During the entire study period, 75 major complications that needed hospital admission occurred in 70 patients. Of these 75 complications, 12 were thrombo-embolic events and 63 were bleeding events. Sixty-seven complications occurred in 2164 patients with aortic valve replacement and eight complications (only bleeding events) occurred in 392 patients with mitral valve replacement. The incidence of thrombo-embolic and bleeding events per patient-year did not differ significantly between the study groups. In detail, thrombo-embolic events occurred in seven patients of the CON group and in five patients of the LOW group. Incidence per patient-year was 0.37 and 0.19% in the CON and LOW groups, respectively (Table 2). Out of the 12 patients with thrombo-embolic events, prolonged reversible ischaemic neurological deficits occurred in three patients, transient ischaemic attacks in eight patients, and valve prosthesis thrombosis in one patient. Concomitant diagnoses were hypertension in eight patients, atrial fibrillation in five patients, and reduced LVEF (30 50%) in four patients. Four patients had fibrinogen Table 2 Incidence of grade III complications according to study group and valve (in % per patient year) LOW group (n¼1327) CON group (n¼1346) Thrombo-embolism Total NS Aortic valve NS Mitral valve or NS double valve Bleeding Total NS Aortic valve NS Mitral valve or double valve NS LOW, low dose; CON, conventional dose; NS, not significant. Significance concentrations of.360 mg/dl (range: mg/dl). Only two patients (without atrial fibrillation) took aspirin (100 mg/day). Thirty-three bleeding events occurred in the CON group and 30 bleeding events in the LOW group. Incidence of bleeding per patient-year was 1.52 and 1.42% in the CON and LOW groups, respectively (Table 2). Figure 1 illustrates the individual courses of the INR values in those patients who developed a major thrombo-embolic event. Data are given for the last 8 weeks before the event occurred. Mean values ranged between 2.08 (SD,
4 2482 H. Koertke et al. Table 3 Causes of death in the study groups Cause of death LOW group (n ¼ 65) CON group (n ¼ 60) Figure 1 Time course of INR values in those patients who developed a thrombo-embolic event. 0.53; 7 weeks prior to the event) and 2.57 (SD, 0.67; 2 weeks prior to the event). In five out of the 12 patients, the INR values were,1.8 when the complication occurred. Only one of these five patients was in the LOW group. Four of the five patients had an INR value of,1.5. In one of these patients, oral anticoagulants were stopped prior to a dental procedure. In seven patients whose INR values were.1.8, the lowest value ranged between 2.0 and 2.3 in the last eight weeks before the complication occurred. Four of these seven patients were 70 years and older and two other patients were older than 64 years. In the patients who developed bleeding events in the LOW group, mean INR values were significantly lower within the last 8 weeks before the bleeding event occurred than in the patients who developed bleeding events in the CON group (P-values,, ), with the exception of weeks 3 and 4. In the LOW group, mean values ranged between 2.29 (SD, 0.38; 7 weeks prior to the event) and 2.55 (SD, 0.59; 2 weeks prior to the event). In the CON group, mean values ranged between 2.76 (SD, 0.55; 5 weeks prior to the event) and 3.03 (SD, 0.92; 1 week prior to the event). One week prior to the event, only 19 patients had INR values of.3.0 and only eight patients had INR values of.3.5. When the event occurred, only 11 patients had INR values of.3.0 and only five patients had INR values of.3.5. In 22 out of the 59 patients, the highest INR value did not exceed 3 (INR values did not exceed 2.5 in six patients) during the last 8 weeks before the complication occurred. Thirteen of the aforementioned 22 patients were in the LOW group and nine in the CON group. Study group, age, LVEF category (.50, 30 50, and,30%, respectively), atrial fibrillation, and diabetes mellitus were not associated with thrombo-embolic or bleeding events in the univariable Cox regression analysis. Thus, no multivariable analysis was performed. Survival rates in the CON and LOW groups were 97.8 and 97.7%, respectively (P.0.05). In detail, 125 patients died during follow-up, 60 patients in the CON group and 65 patients in the LOW group (P.0.05). Causes of death are listed in Table 3. Potentially anticoagulation-related deaths did not differ significantly between the study groups (P.0.05). Discussion The principle finding of this large randomized, prospective interventional trial is that in patients with INR Intraoperative death 0 1 Potentially anticoagulation-related death Cardiac, cerebral, or intestinal 2 2 bleeding Embolism 1 0 Stroke 1 2 Cardiac-related death Cardiogenic shock 3 2 Acute cardiac failure/ 9 11 myocardial infarction Atrial or ventricular fibrillation 6 7 Cardiomyopathy Others Unknown 6 4 self-management the incidence of grade III thromboembolic events was low, even when the target INR range was only for patients with aortic valve replacement. In the subgroup of patients with mitral or double valve replacement (19% of the study population), no major thrombo-embolic events occurred with a target INR range of Several medical associations have published guidelines on oral anticoagulants for patients with mechanical heart valve prosthesis. The European Society of Cardiology 8 has recommended an INR of for second-generation valves in the mitral, whereas an INR of was considered sufficient for second-generation valves in the aortic. The American College of Cardiology and the American Heart Association guidelines of recommend an INR of for aortic valve replacement with bileaflet mechanical or Medtronic Hall prostheses in patients with no risk factors. If a patient has risk factors, oral anticoagulants are indicated to achieve an INR of After aortic valve replacement with other mechanical valves, or after mitral valve replacement, an INR of is also recommended. The quality of oral anticoagulation determines both thrombo-embolic and bleeding complications. A high percentage of INR values within the target range can significantly reduce the incidence of thrombo-embolic events. 1,2 In the subgroup of patients with mitral or double valve replacement, both the CON group and the LOW group had mean INR values close to the recommended INR level of In addition, both groups had a high percentage of INR values within their target range. Our data demonstrate that the recommended INR target level of 3.0 in combination with INR self-management is indeed able to guarantee a very low risk of thrombo-embolic events in patients with mitral or double valve replacement. An INR target range of is only recommended in patients after aortic valve replacement with bileaflet mechanical or Medtronic Hall prostheses with no risk factors, such as atrial fibrillation, left-ventricular dysfunction, previous thrombo-embolism, or hypercoagulable condition. 4 In our patients with aortic valve replacement, the INR target range of in the LOW group did not result in a
5 Low-dose INR self-management 2483 higher incidence of thrombo-embolic complications compared with the CON group with an INR target range of In line with our results, an earlier randomized trial in patients with tissue heart valve replacement 9 demonstrated that all major hemorrhagic complications occurred in the standard INR group ( ) and none in the group with INR , indicating that a less intensive regimen is neither less effective nor less safe than standard anticoagulant therapy. The occurrence of thrombo-embolic events might be explained by several factors. First, in our study, the INR values were,1.5 and thus very low in some patients when the event occurred. Secondly, some patients had known risk factors such as atrial fibrillation, left-ventricular dysfunction, and high fibrinogen concentrations. In line with recent guidelines, an INR target range of,2.5 was probably too low for these patients. Thirdly, additional risk factors such as hypertension, diabetes, post-operative infection, and a history of cancer increase the risk of thrombo-embolic events, even when an INR target range of is recommended. 10 Finally, not all ischaemic neurological attacks are related to cardio-embolism. Embolic events are a well-known serious complication that is often observed in elderly. 11 The aetiology is of multiple origins and is at least in part due to an increased risk of dehydration caused by age-related changes in kidney function, thirst perception, body water content, and homeostatic capacity. 12 There is a clear relations between anticoagulation intensity and the incidence of bleeding events. With an increasing duration of treatment, a cumulative increase in the risk of major haemorrhage is generally observed. 13 The annual incidence of major haemorrhage (defined as intracranial haemorrhage or haemorrhage causing death or necessitating transfusion or hospitalization) has ranged between 1.2 and 7.0 episodes per 100 patients in different cohort studies, 14 whereas in clinical trials with selected patients populations it has ranged between 0.5 and 4.2 per 100 patients. 13 Minor bleeding episodes (those that have no costs or consequences) have an annual incidence of 2 24 episodes per 100 patients, depending on the target INR range. 15 In our study, the incidence of major bleeding events was at the lower range of published data and was very similar in the CON and LOW groups. This might be explained by the fact that the mean INR values were relatively close together between the study groups. These results might be due to the fact that the training course for INR self-management was identical for all study participants and was performed before patients were randomized to the study groups. In general, data support earlier results that self-monitoring in a selected patient population is feasible and is able to influence and improve the quality of INR management. 1,2 Since the biological half-life of vitamin K-dependent clotting factors is 2 4 days, 16 a recently measured INR value is a good predictor of the risk of developing a bleeding event in the near future. The majority of our patients had INR values of,3.0 within the last week before the bleeding event occurred. Most INR values were within the group-specific target range. Obviously, even the recommended INR target range of is not safe for all patients on oral anticoagulant therapy. 4 As mentioned before, an INR value which is.2.3 but,3.0 can already be life-threatening. 5 There are several reasons why relatively low INR values can be associated with major bleeding events. First, vessel anomalies such as intracranial aneurysms might increase the risk of bleeding events in some patients. Secondly, hypertension, which was frequently present in both the CON and the LOW groups, can increase the risk of a bleeding complication if insufficient medical treatment leads to a rise in blood pressure. Thirdly, polymorphisms in the enzymes that are responsible for the metabolism of oral anticoagulants (cytochrome P 450 CYP2C9) or function as drug target (vitamin K epoxide reductase) have been described These polymorphisms might account for up to 50% of the interindividual variability in INR values. 18 Specific CYP2C9 variants are associated with a higher risk of bleeding events. 17 Although the bleeding complications in the present trial with an INR time within the target range of 75% was only 1.5%, this complication rate was several times higher than the rate of major thrombo-embolic complications. Consequently, there is a rationale for investigating in future studies whether or not INR self-management provides an opportunity to reduce further the INR target range and the risk of major haemorrhage without unacceptably increasing the risk of major thrombo-embolic events. In summary, our data demonstrate that low-dose INR selfmanagement does not increase the risk of thrombo-embolic events compared with conventional dose INR selfmanagement. However, with the currently recommended target range, the risk of bleeding complications is still unsatisfactorily high. Conflict of interest: none declared. Funding This study was funded by the Heart and Diabetes Center North Rhine-Westfalia, Germany. References 1. Körtke H, Minami K, Breymann T, Seifert D, Baraktaris A, Wagner O, Kleikamp G, el-banayosy A, Mirow N, Körfer R. INR self-management after mechanical heart valve replacement: ESCAT (Early Self-Controlled Anticoagulation Trial). Z Kardiol 2001;90(Suppl. 6):VI/ Koertke H, Zittermann A, Wagner O, Koerfer R. Self-management of oral anticoagulation therapy improves long-term survival in patients with mechanical heart valve replacement. Ann Thorac Surg 2007;83: Koertke H, Zittermann A, Minami K, Tenderich G, Wagner O, El-Arousy M, Krian A, Ennker J, Taborski U, Klövekorn WP, Moosdorf R, Saggau W, Morshuis M, Koerfer J, Seifert D, Koerfer R. Low dose INR-self-management a promising tool to achieve low complication rates after mechanical heart valve replacement. Ann Thorac Surg 2005; 79: ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): Developed in Collaboration With the Cardiovascular Angiography and Interventions and the Society of Thoracic Society of Cardiovascular Anesthesiologists: Endorsed by the Society Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. Circulation 2006;114: Oden A, Fahlen M. Oral anticoagulation and risk of death: a medical record linkage study. Br Med J 2002;325: Koertke H, Zittermann A, Mommertz S, Koerfer R. The bad Oeynhausen concept of INR-self-management. J Thromb Thrombolysis 2005;19: Koertke H, Minami K, Boethig D, Breymann T, Seifert D, Wagner O, Atmacha N, Krian A, Ennker J, Taborski U, Klövekorn WP, Moosdorf R, Saggau W, Koerfer R. INR self-management permits lower anticoagulation levels after mechanical heart valve replacement. Circulation 2003; 108(Suppl. 1):II75 II78.
6 2484 H. Koertke et al. 8. Gohlke-Barwolf C, Acar J, Oakley C, Butchart E, Burckhart D, Bodnar E, Hall R, Delahaye JP, Horstkotte D, Kremer R, Krayenbuh HP, Krzeminska-Pakula M, Samama M. Guidelinjes for prevention of thromboembolic events in valvular heart disease: Study Group of the Working Group on Valvular Heart Disease of the European Society of Cardiology. Eur Heart J 1995;16: Turpie AG, Gunstensen J, Hirsh J, Nelson H, Gent M. Randomised comparison of two intensities of oral anticoagulant therapy after tissue heart valve replacement. Lancet 1988;I: Butchart EG, Ionescu A, Payne N, Giddings J, Grunkemeier GL, Fraser AG. A new scoring system to determine thromboembolic risk after heart valve replacement. Circulation 2003;108(Suppl. II):II68 II Minami K, Zittermann A, Schulte-Eistrup S, Koertke H, Koefer R. Mitroflow synergy prostheses for aortic valve replacement: 19 years experience with 1,516 patients. Ann Thorac Surg 2005;80: Volkert D, Kreuel K, Stehle P. Nutrition beyond 65-amount of usual drinking fluid and motivation to drink are interrelated in community-living, independent elderly people. Z Gerontol Geriatr 2004;37: (in German). 13. Levine MN, Raskob G, Landefeld S, Kearon C. Hemorrhagic complications of anticoagulant treatment. Chest 2001;119(Suppl.):108S 121S. 14. Schulman S. Oral anticoagulation. In: Beutler E, Lichtman MA, Coller BS, Kipps TJ, Seligsohn U, eds. Williams Haematology. 6th ed. New York: McGraw-Hill; pp Schulman S. Care of patients receiving long-term anticoagulant therapy. New Engl J Med 2003;349: Vigano S, Mannucci PM, Solinas S, Bottasso B, Mariani G. Decrease in protein C antigen and formation of an abnormal protein soon after starting oral anticoagulant therapy. Brit J Haematol 1984;57: Hummers-Pradier E, Hess S, Adham IM, Papke T, Pieske B, Kochen MM. Determination of bleeding risk using genetic markers in patients taking phenprocoumon. Eur J Clin Pharmacol 2003;59: Bodin L, Verstuyft C, Tregouet DA, Robert A, Dubert L, Funck-Brentano C, Jaillon P, Beaume P, Laurtent-Puig P, Becquemont L, Loriot MA. Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood 2005;106: D Andrea G, D Ambrosio RL, Di Perna P, Chetta M, Santacroce R, Brancaccio V, Grandone E, Margaglione M. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 2005;105:
Low-Dose International Normalized Ratio Self-Management: A Promising Tool to Achieve Low Complication Rates After Mechanical Heart Valve Replacement
Low-Dose International Normalized Ratio Self-Management: A Promising Tool to Achieve Low Complication Rates After Mechanical Heart Valve Replacement Heinrich Koertke, MD, Armin Zittermann, PhD, Kazutomo
More informationSelf-Management of Oral Anticoagulation Therapy Improves Long-Term Survival in Patients With Mechanical Heart Valve Replacement
CARDIOVASCULAR ORIGINAL ARTICLES: CARDIOVASCULAR Self-Management of Oral Anticoagulation Therapy Improves Long-Term Survival in Patients With Mechanical Heart Valve Replacement Heinrich Koertke, MD, Armin
More informationIntensity of oral anticoagulation after implantation of St. Jude Medical mitral or multiple valve replacement: lessons learned from GELIA (GELIA 5)
European Heart Journal Supplements () 3 (Supplement Q), Q39 Q43 Intensity of oral anticoagulation after implantation of St. Jude Medical mitral or multiple valve replacement: lessons learned from GELIA
More informationAlthough numerous mechanical and biologic heart
International Normalized Ratio Self-Management After Mechanical Heart Valve Replacement: Is an Early Start Advantageous? Heinrich Körtke, MD, and Reiner Körfer, MD Department of Thoracic and Cardiovascular
More informationMitroflow Synergy Prostheses for Aortic Valve Replacement: 19 Years Experience With 1,516 Patients
Mitroflow Synergy Prostheses for Aortic Valve Replacement: 19 Years Experience With 1,516 Patients Kazutomo Minami, MD, Armin Zittermann, PhD, Sebastian Schulte-Eistrup, MD, Heinrich Koertke, MD, and Reiner
More informationInternational Normalized Ratio Self-Management Lowers the Risk of Thromboembolic Events After Prosthetic Heart Valve Replacement
International Normalized Ratio Self-Management Lowers the Risk of Thromboembolic Events After Prosthetic Heart Valve Replacement Thomas Eitz, MD, Soren Schenk, MD, Dirk Fritzsche, MD, Andreas Bairaktaris,
More informationUpdate on Oral Anticoagulation for Mechanical Heart Valves
Update on Oral Anticoagulation for Mechanical Heart Valves Douglas C. Anderson, Pharm.D., D.Ph. Professor and Chair Dept. of Pharmacy Practice Cedarville University School of Pharmacy OHIO SOCIETY OF HEALTH-SYSTEM
More informationIntroduction. Keywords: Infrainguinal bypass; Prognosis; Haemorrhage; Anticoagulants; Antiplatelets.
Eur J Vasc Endovasc Surg 30, 154 159 (2005) doi:10.1016/j.ejvs.2005.03.005, available online at http://www.sciencedirect.com on Risk of Major Haemorrhage in Patients after Infrainguinal Venous Bypass Surgery:
More informationSubclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: an observational study
Subclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: an observational study Meagan Sullivan, PharmD PGY2 Cardiology Pharmacy Resident University of Chicago Medicine
More informationSimultaneous Aortic and Mitral Valve Replacement in Octogenarians: A Viable Option?
Simultaneous Aortic and Mitral Valve Replacement in Octogenarians: A Viable Option? Ariane Maleszka, MD,* Georg Kleikamp, MD, PhD,* Armin Zittermann, PhD, Maria R. G. Serrano, MD, and Reiner Koerfer, MD,
More informationDepartment of Cardiac Surgery, Trousseau University Hospital, Tours, France
Risk Factors for Valve-Related Complications after Mechanical Heart Valve Replacement in 505 Patients with Long-Term Follow Up Thierry Bourguignon, Eric Bergöend, Alain Mirza, Grégoire Ayegnon, Paul Neville,
More informationAntithrombotic Therapy in Patients with Atrial Fibrillation
Antithrombotic Therapy in Patients with Atrial Fibrillation June Soo Kim, M.D., Ph.D. Department of Medicine Cardiac & Vascular Center, Samsung Medical Center Sungkyunkwan University School of Medicine
More informationSupplementary Online Content
Supplementary Online Content Inohara T, Manandhar P, Kosinski A, et al. Association of renin-angiotensin inhibitor treatment with mortality and heart failure readmission in patients with transcatheter
More informationPrimary Care practice clinics within the Edmonton Southside Primary Care Network.
INR Monitoring and Warfarin Dose Adjustment Last Review: November 2016 Intervention(s) and/or Procedure: Registered Nurses (RNs) adjust warfarin dosage according to individual patient International Normalized
More informationClinical Practice Committee Anticoagulation Bridging Document
Original: 10/23/06 Last Updated: 10/30/07 Clinical Practice Committee Do patients on long term oral anticoagulant therapy who require short term interruption of warfarin for an elective invasive procedure
More informationLong-term bleeding events after mechanical aortic valve replacement in patients under the age of 60
Neth Heart J (2015) 23:111 115 DOI 10.1007/s12471-014-0626-9 ORIGINAL ARTICLE Long-term bleeding events after mechanical aortic valve replacement in patients under the age of 60 B. M. Swinkels & B. A.
More informationThe effects of a low international normalized ratio on thromboembolic and bleeding complications in patients with mechanical mitral valve replacement
Bal et al. Journal of Cardiothoracic Surgery 2014, 9:79 RESEARCH ARTICLE Open Access The effects of a low international normalized ratio on thromboembolic and bleeding complications in patients with mechanical
More informationDepartment of Cardiothoracic Surgery, Heart and Lung Center, Lund University Hospital, Lund, Sweden
Long-Term Outcome of the Mitroflow Pericardial Bioprosthesis in the Elderly after Aortic Valve Replacement Johan Sjögren, Tomas Gudbjartsson, Lars I. Thulin Department of Cardiothoracic Surgery, Heart
More informationSafety of Arthrocentesis and Joint Injection in Patients Receiving Anticoagulation at Therapeutic Levels
CLINICAL RESEARCH STUDY Safety of Arthrocentesis and Joint Injection in Patients Receiving Anticoagulation at Therapeutic Levels Imdad Ahmed, MBBS, a,b Elie Gertner, MD a,b a Department of Internal Medicine,
More informationResults from RE-LY and RELY-ABLE
Results from RE-LY and RELY-ABLE Assessment of the safety and efficacy of dabigatran etexilate (Pradaxa ) in longterm stroke prevention EXECUTIVE SUMMARY Dabigatran etexilate (Pradaxa ) has shown a consistent
More informationLong-Term Care Updates
Long-Term Care Updates October/November 2015 By Daniel Kerner, PharmD A stroke occurs when blood flow to the brain is stopped or slowed, resulting in death or damage to brain cells. There are three main
More informationTable 1 Baseline characteristics of 60 hemodialysis patients with atrial fibrillation and warfarin use
Table 1 Baseline characteristics of 60 hemodialysis patients with atrial fibrillation and warfarin use Baseline characteristics Users (n = 28) Non-users (n = 32) P value Age (years) 67.8 (9.4) 68.4 (8.5)
More informationAnticoagulation Therapy and Valve Surgery. Dr Pau Kiew Kong Consultant Cardiothoracic Surgeon
Anticoagulation Therapy and Valve Surgery Dr Pau Kiew Kong Consultant Cardiothoracic Surgeon Outline of lecture 1. Type of Valve Surgery 2. Anticoagulation requirements 3. Mechanical (Metallic) prosthetic
More informationTransient Atrial Fibrillation and Risk of Stroke after Acute Myocardial Infarction
Transient Atrial Fibrillation and Risk of Stroke after Acute Myocardial Infarction Doron Aronson MD, Gregory Telman MD, Fadel BahouthMD, Jonathan Lessick MD, DSc and Rema Bishara MD Department of Cardiology
More information16 YEAR RESULTS Carpentier-Edwards PERIMOUNT Mitral Pericardial Bioprosthesis, Model 6900
CLINICAL COMMUNIQUé 6 YEAR RESULTS Carpentier-Edwards PERIMOUNT Mitral Pericardial Bioprosthesis, Model 69 The Carpentier-Edwards PERIMOUNT Mitral Pericardial Valve, Model 69, was introduced into clinical
More informationAPPENDIX A NORTH AMERICAN SYMPTOMATIC CAROTID ENDARTERECTOMY TRIAL
APPENDIX A Primary Findings From Selected Recent National Institute of Neurological Disorders and Stroke-Sponsored Clinical Trials That Have shaped Modern Stroke Prevention Philip B. Gorelick 178 NORTH
More informationSangho Rhie, M.D.*, Jun Young Choi, M.D.*, In Seok Jang, M.D.*, Jong Woo Kim, M.D.*, Chung Eun Lee, M.D.*, Hyun Oh Park, M.D.*
Korean J Thorac Cardiovasc Surg 2011;44:220-224 ISSN: 2233-601X (Print) ISSN: 2093-6516 (Online) Clinical Research DOI:10.5090/kjtcs.2011.44.3.220 Relationship between the Occurrence of Thromboembolism
More informationTelemedicine-guided, very low-dose international normalized ratio self-control in patients with mechanical heart valve implants
European Heart Journal (2015) 36, 1297 1305 doi:10.1093/eurheartj/ehu330 CLINICAL RESEARCH Thrombosis and antithrombotic therapy Telemedicine-guided, very low-dose international normalized ratio self-control
More informationCorrelation between demographic factors and warfarin stable dosage in population of Western China.
Biomedical Research 2017; 28 (19): 8249-8253 ISSN 0970-938X www.biomedres.info Correlation between demographic factors and warfarin stable dosage in population of Western China. Yongfeng Fan 1,2, Li Dong
More informationComorbidity or medical history Existing diagnoses between 1 January 2007 and 31 December 2011 AF management care AF symptoms Tachycardia
Supplementary Table S1 International Classification of Disease 10 (ICD-10) codes Comorbidity or medical history Existing diagnoses between 1 January 2007 and 31 December 2011 AF management care I48 AF
More informationKCS Congress: Impact through collaboration
Stroke Prevention in Atrial Fibrillation (SPAF) in Kenya Elijah N. Ogola FACC University of Nairobi Kenya Cardiac Society Annual Scientific Congress Mombasa 28 th June 1 st July 2017 KCS Congress: Impact
More informationSupplementary Online Content. Abed HS, Wittert GA, Leong DP, et al. Effect of weight reduction and
1 Supplementary Online Content 2 3 4 5 6 Abed HS, Wittert GA, Leong DP, et al. Effect of weight reduction and cardiometabolic risk factor management on sympton burden and severity in patients with atrial
More informationCondition Congestive heart failure I11.0; I13.0; I13.2; I42.0; I50 CO3C Left ventricular dysfunction I50.1; I50.9 E11 1; E11 9
Comparative effectiveness and safety of non-vitamin K antagonists oral anticoagulants (OACs) and warfarin in daily clinical practice: A propensity weighted nationwide cohort study. Supplementary material
More informationAnticoagulation in Special populations. Ng Heng Joo Department of Haematology Singapore General Hospital
Anticoagulation in Special populations Ng Heng Joo Department of Haematology Singapore General Hospital roymatheson.com Objectives Safer anticoagulation for The elderly Chronic kidney disease Obese patients
More informationSpotlight on valvular heart disease guidelines. Prosthetic heart valves. Bernard Iung Bichat Hospital, Paris Diderot University Paris, France
Spotlight on valvular heart disease guidelines. Prosthetic heart valves. Bernard Iung Bichat Hospital, Paris Diderot University Paris, France Faculty disclosure First name - last name I disclose the following
More informationNorth Wales Cardiac Network Guidelines on oral antiplatelet therapy in cardiovascular disease
Guidelines on oral antiplatelet therapy in cardiovascular disease This guidance should be considered as one part of the wider therapeutic management of patients. The indication for antiplatelet therapy
More informationThe randomized study of efficiency and safety of antithrombotic therapy in
.. [ ] 18 150 160 mg/d 2 mg/d INR 2.0 3.0( 75 INR 1.6 2.5) 704 369 335 420 59.7% 63.3 9.9 19 2 24 2.7% 6.0% P =0.03 OR 0.44 95% CI 0.198 0.960 56% 62% 1.8% 4.6% P =0.04 OR 0.38 95% CI 0.147 0.977 52% 10.6%
More informationCASE IN... Anticoagulation: When to Start,When to Stop. The management of patients who require an. Meet Tracey. Anticoagulation
Anticoagulation: When to Start,When to Stop Ebtisam Bakhsh, MD; and James D. Douketis, MD, FRCPC Presented at McMaster University s Thrombosis and Hematology Update, October 2006. CASE IN... Anticoagulation
More informationPerformance and Quality Measures 1. NQF Measure Number. Coronary Artery Disease Measure Set
Unless indicated, the PINNACLE Registry measures are endorsed by the American College of Cardiology Foundation and the American Heart Association and may be used for purposes of health care insurance payer
More informationPrimary Prevention of Stroke
Primary Prevention of Stroke Dr Chris Ellis Cardiologist Green Lane CVS Service, Auckland City Hospital & Auckland Heart Group, Mercy Hospital, Auckland 67 Pages Long, 735 References 29 Sub-Headings for
More informationOn October 3, 1977, the first St. Jude Medical (SJM)
The St. Jude Medical Cardiac Valve Prosthesis: A 25-Year Experience With Single Valve Replacement Robert W. Emery, MD, Christopher C. Krogh, Kit V. Arom, MD, PhD, Ann M. Emery, RN, Kathy Benyo-Albrecht,
More informationHeart Valves: Before and after surgery
Heart Valves: Before and after surgery Tim Sutton, Consultant Cardiologist Middlemore Hospital, Auckland Auckland Heart Group Indications for intervention in Valvular disease To prevent sudden death and
More informationAnticoagulation in Special populations. Ng Heng Joo Department of Haematology Singapore General Hospital
Anticoagulation in Special populations Ng Heng Joo Department of Haematology Singapore General Hospital roymatheson.com Objectives Safer anticoagulation for The elderly Chronic kidney disease Obese patients
More informationDr Julia Hopyan Stroke Neurologist Sunnybrook Health Sciences Centre
Dr Julia Hopyan Stroke Neurologist Sunnybrook Health Sciences Centre Objectives To learn what s new in stroke care 2010-11 1) Acute stroke management Carotid artery stenting versus surgery for symptomatic
More informationApixaban for stroke prevention in atrial fibrillation. August 2010
Apixaban for stroke prevention in atrial fibrillation August 2010 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationBehavior of Prothrombin Time (INR) in Response to Warfarin Therapy in a Thai Population
Behavior of Prothrombin Time (INR) in Response to Warfarin Therapy in a Thai Population Sarana Boonbaichaiyapruck,MD, FACC* Pradit Panchavinnin,MD.** Taworn Suthichaiyakul,MD.*** Thanawat Benjanuwatra,MD.****
More informationEchocardiography analysis in renal transplant recipients
Original Research Article Echocardiography analysis in renal transplant recipients S.A.K. Noor Mohamed 1*, Edwin Fernando 2, 1 Assistant Professor, 2 Professor Department of Nephrology, Govt. Stanley Medical
More informationPresenter Disclosure. Patrick O. Myers, M.D. No Relationships to Disclose
Presenter Disclosure Patrick O. Myers, M.D. No Relationships to Disclose Aortic Valve Repair by Cusp Extension for Rheumatic Aortic Insufficiency in Children Long term Results and Impact of Extension Material
More informationStroke secondary prevention. Gill Cluckie Stroke Nurse Consultant St. George s Hospital
Stroke secondary prevention Gill Cluckie Stroke Nurse Consultant St. George s Hospital Stroke recurrence The risk of recurrent stroke is greatest after first stroke 2 3% of survivors of a first stroke
More informationTechnology appraisal guidance Published: 15 March 2012 nice.org.uk/guidance/ta249
Dabigatran an etexilate for the preventionention of stroke and systemic embolism in atrial fibrillation Technology appraisal guidance Published: 15 March 2012 nice.org.uk/guidance/ta249 NICE 2012. All
More informationOnline Appendix (JACC )
Beta blockers in Heart Failure Collaborative Group Online Appendix (JACC013117-0413) Heart rate, heart rhythm and prognostic effect of beta-blockers in heart failure: individual-patient data meta-analysis
More informationA COhort of antithrombotic use and. atrial fibrillation in Thailand (COOL AF Thailand)
A COhort of antithrombotic use and Optimal INR Level in patients with nonvalvular atrial fibrillation in Thailand (COOL AF Thailand) Prevalence of Atrial Fibrillation Number of AF Patients Predicted to
More informationThe ATS Medical Open Pivot heart valve (ATS Medical, 10-Year Experience With the ATS Mechanical Valve in the Mitral Position
10-Year Experience With the ATS Mechanical Valve in the Mitral Position Constantin Stefanidis, MD, Albert M. Nana, MD, Didier De Cannière, MD, PhD, Martine Antoine, MD, Jean-Luc Jansens, MD, Chi-Hoang
More informationLeft atrium appendage closure: A new technique for patients at high hemorrhagic risk
Left atrium appendage closure: A new technique for patients at high hemorrhagic risk Victoria Martin Yuste MD PhD ITC. Cardiology Department. Hospital Clinic. Barcelona SITE. Barcelona, Juin-9-2013 NON
More informationIs Apixaban Effective for the Prevention of Stroke in Patients With Non-Valvular Atrial Fibrillation?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2014 Is Apixaban Effective for the Prevention
More informationIschemic Stroke in Critically Ill Patients with Malignancy
Ischemic Stroke in Critically Ill Patients with Malignancy Jeong-Am Ryu 1, Oh Young Bang 2, Daesang Lee 1, Jinkyeong Park 1, Jeong Hoon Yang 1, Gee Young Suh 1, Joongbum Cho 1, Chi Ryang Chung 1, Chi-Min
More informationThe PROACT Trial: valve choice has changed
The PROACT Trial: valve choice has changed Marc W. Gerdisch, MD On behalf of the PROACT Investigators; Chief Cardiovascular and Thoracic Surgery Co-director Franciscan Heart Valve Center Cardiac Surgery
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Solomon SD, Uno H, Lewis EF, et al. Erythropoietic response
More informationSupplementary Online Content
Supplementary Online Content Inohara T, Xian Y, Liang L, et al. Association of intracerebral hemorrhage among patients taking non vitamin K antagonist vs vitamin K antagonist oral anticoagulants with in-hospital
More informationManuel Castella MD PhD Hospital Clínic, University of
Manuel Castella MD PhD Hospital Clínic, University of Barcelona mcaste@clinic.ub.es @mcastellamd www.escardio.org/guidelines European Heart Journal - doi:10.1093/eurheartj/ehw210 Providing integrated care
More informationWATCHMAN PROTECT AF Study Rev. 6
WATCHMAN PROTECT AF Study Rev. 6 Protocol Synopsis Title WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients with Atrial Fibrillation (PROTECT AF) Sponsor Atritech/Boston Scientific
More informationShow Me the Outcomes!
Show Me the Outcomes! Real-World Safety Data on Oral Anticoagulants in Nonvalvular Atrial Fibrillation Gabby Anderson, PharmD PGY1 Pharmacy Resident anderson.gabrielle@mayo.edu Pharmacy Grand Rounds October
More informationPage 1. Current Trends in the Management of Atrial Fibrillation: Left Atrial Appendage Occlusion. Atrial fibrillation: Scope of the problem
Current Trends in the Management of Atrial Fibrillation: Left Atrial Appendage Occlusion Benjamin A. D Souza, MD, FACC, FHRS Assistant Professor of Clinical Medicine Penn Presbyterian Medical Center Cardiac
More informationCE: Swati; MBC/200710; Total nos of Pages: 6; MBC Original article 1. Blood Coagulation and Fibrinolysis 2010, 21:
Original article 1 The c.-1639g>a polymorphism of the VKORC1 gene in Serbian population: retrospective study of the variability in response to oral anticoagulant therapy Mirjana K. Kovac a, Aleksandar
More informationFølgende dias er fremlagt ved DCS / DTS Fællesmøde 13. januar 2011 og alle rettigheder tilhører foredragsholderen. Gengivelse må kun foretages ved
. Følgende dias er fremlagt ved DCS / DTS Fællesmøde 13. januar 2011 og alle rettigheder tilhører foredragsholderen. Gengivelse må kun foretages ved tilladelse Antithrombotic therapy in Atrial Fibrillation
More informationMedical Apps for Cardiology Uses. There s an App for That!
Medical Apps for Cardiology Uses There s an App for That! Audience Participation Question #1 1. ASCVD Risk App What is the predicted 10 year CV event rate for a 57 y/o black male patient with treated
More informationShould We Reconsider using Anticoagulation for Biological Tissue Valves
Should We Reconsider using Anticoagulation for Biological Tissue Valves No Disclosures Disclosures Watching grass grow Complete with audio 1 hour 8 minutes 9884 views Subclinical Leaflet Thrombosis in
More informationDr Ben Turner. Consultant Neurologist and Honorary Senior Lecturer Barts and The London NHS Trust London Bridge Hospital
Stroke Management Dr Ben Turner Consultant Neurologist and Honorary Senior Lecturer Barts and The London NHS Trust London Bridge Hospital Introduction Stroke is the major cause of disability in the developed
More informationC1: Medical Standards for Safety Critical Workers with Cardiovascular Disorders
C1: Medical Standards for Safety Critical Workers with Cardiovascular Disorders GENERAL ISSUES REGARDING MEDICAL FITNESS-FOR-DUTY 1. These medical standards apply to Union Pacific Railroad (UPRR) employees
More informationInvasive and Medical Treatments for Atrial Fibrillation. Thomas J Dresing, MD Section of Electrophysiology and Pacing Cleveland Clinic
Invasive and Medical Treatments for Thomas J Dresing, MD Section of Electrophysiology and Pacing Cleveland Clinic Disclosures Fellow s advisory panel for St Jude Medical Speaking honoraria from: Boston
More informationHERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) DABIGATRAN RECOMMENDED What it is Indications Date decision last revised
Name: generic (trade) Dabigatran etexilate (Pradaxa ) HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) DABIGATRAN RECOMMENDED What it is Indications Date decision last revised Direct thrombin inhibitor
More informationV. Roldán, F. Marín, B. Muiña, E. Jover, C. Muñoz-Esparza, M. Valdés, V. Vicente, GYH. Lip
PLASMA VON WILLEBRAND FACTOR LEVELS ARE AN INDEPENDENT RISK FACTOR ADVERSE EVENTS IN HIGH RISK ATRIAL FIBRILLATION PATIENTS TAKING ORAL ANTICOAGULATION THERAPY V. Roldán, F. Marín, B. Muiña, E. Jover,
More informationEffect of Valve Suture Technique on Incidence of Paraprosthetic Regurgitation and 10-Year Survival
Effect of Valve Suture Technique on Incidence of Paraprosthetic Regurgitation and 10-Year Survival Sukumaran K. Nair, FRCS (C Th), Gauraang Bhatnagar, MBBS, Oswaldo Valencia, MD, and Venkatachalam Chandrasekaran,
More informationGRAND ROUNDS - DILEMMAS IN ANTICOAGULATION AND ANTIPLATELET THERAPY. Nick Collins February 2017
GRAND ROUNDS - DILEMMAS IN ANTICOAGULATION AND ANTIPLATELET THERAPY Nick Collins February 2017 DISCLOSURES Before I commence Acknowledge.. Interventional Cardiologist Perception evolved. Interventional
More informationCLINICAL COMMUNIQUE 16 YEAR RESULTS
CLINICAL COMMUNIQUE 6 YEAR RESULTS Carpentier-Edwards PERIMOUNT Mitral Pericardial Bioprosthesis, Model 6900 Introduction The Carpentier-Edwards PERIMOUNT Mitral Pericardial Valve, Model 6900, was introduced
More informationNOAs for stroke prevention in Atrial Fibrillation: potential advantages in the elderly patients. Giancarlo Agnelli
NOAs for stroke prevention in Atrial Fibrillation: potential advantages in the elderly patients Giancarlo Agnelli Internal & Cardiovascular Medicine - Stroke Unit University of Perugia, Italy My talk today
More informationOcclusion de l'auricule gauche: Niche ou réel avenir? D Gras, MD, Nantes, France
Occlusion de l'auricule gauche: Niche ou réel avenir? D Gras, MD, Nantes, France LAA Occlusion Is there a real future? Background Protect AF Trial Other Studies CAP, ASAP, Prevail Left Atrial Appendage
More informationAtrial Fibrillation and You
Atrial Fibrillation and You Dr Matthew Fay General Practitioner AFA Medical Advisory Committee Member NHS-Improvement Clinical Lead AF & U Dr Matthew Fay General Practitioner AFA Medical Advisory Committee
More informationESC Congress 2011 SIMULTANEOUS HYBRID REVASCULARIZATION OF CAROTID AND CORONARY DISEASE INITIAL RESULTS OF A NEW THERAPEUTIC APPROACH
ESC Congress 2011 SIMULTANEOUS HYBRID REVASCULARIZATION OF CAROTID AND CORONARY DISEASE IN PATIENTS WITH ACUTE CORONARY SYNDROME: INITIAL RESULTS OF A NEW THERAPEUTIC APPROACH AUTHORS: Marta Ponte 1, RICARDO
More informationValve Disease in Patients With Heart Failure TAVI or Surgery? Miguel Sousa Uva Hospital Cruz Vermelha Lisbon, Portugal
Valve Disease in Patients With Heart Failure TAVI or Surgery? Miguel Sousa Uva Hospital Cruz Vermelha Lisbon, Portugal I have nothing to disclose. Wide Spectrum Stable vs Decompensated NYHA II IV? Ejection
More informationAtrial Fibrillaiton and Heart Failure: Anticoagulation therapy in all cases?
Atrial Fibrillaiton and Heart Failure: Anticoagulation therapy in all cases? Nicolas Lellouche Fédération de Cardiologie Hôpital Henri Mondor Créteil Disclosure Statement of Financial Interest I currently
More informationComplicanze aritmiche in riabilitazione dopo CCH.
Complicanze aritmiche in riabilitazione dopo CCH www.fisiokinesiterapia.biz Post-Operative Atrial Fibrillation The rate of AF after cardiac surgery in the 1970s was about 10%, and is now consistently at
More informationDespite improvements in valve design, stroke remains a serious
Surgery for Acquired Cardiovascular Disease Bando et al Early and late stroke after mitral valve replacement with a mechanical prosthesis: Risk factor analysis of a 24-year experience Ko Bando, MD a Junjiro
More information2017 Cardiovascular Symposium CARDIAC SURGERY UPDATE: SMALLER INCISIONS AND LESS COUMADIN DAVID L. SAINT, MD
2017 Cardiovascular Symposium CARDIAC SURGERY UPDATE: SMALLER INCISIONS AND LESS COUMADIN DAVID L. SAINT, MD David L Saint M.D. Tallahassee Memorial Hospital Southern Medical Group Division of Cardiothoracic
More informationWhen and how to combine antiplatelet agents and anticoagulant?
When and how to combine antiplatelet agents and anticoagulant? Christophe Beauloye, MD, PhD Head, Division of Cardiology Cliniques Universitaires Saint-Luc Brussels, Belgium Introduction Anticoagulation
More informationApixaban for Atrial Fibrillation in Patients with End-Stage Renal Disease on Dialysis
Apixaban for Atrial Fibrillation in Patients with End-Stage Renal Disease on Dialysis Caitlin Reedholm, PharmD PGY1 Pharmacy Resident St. David s South Austin Medical Center November 2, 2018 Abbreviations
More informationMitral Valve Repair Versus Replacement in Simultaneous Mitral and Aortic Valve Surgery for Rheumatic Disease
Mitral Valve Repair Versus Replacement in Simultaneous Mitral and Aortic Valve Surgery for Rheumatic Disease Kenji Kuwaki, MD, PhD, Nobuyoshi Kawaharada, MD, PhD, Kiyofumi Morishita, MD, PhD, Tetsuya Koyanagi,
More informationPros and Cons of Individual Agents Based on Large Trial Results: RELY, ROCKET, ARISTOTLE, AVERROES
Pros and Cons of Individual Agents Based on Large Trial Results: RELY, ROCKET, ARISTOTLE, AVERROES Ralph L. Sacco, MS MD FAAN FAHA Olemberg Family Chair in Neurological Disorders Miller Professor of Neurology,
More informationSUPPLEMENTAL MATERIAL
SUPPLEMENTAL MATERIAL Table S1: Number and percentage of patients by age category Distribution of age Age
More informationNeuroPI Case Study: Anticoagulant Therapy
Case: An 82-year-old man presents to the hospital following a transient episode of left visual field changes. His symptoms lasted 20 minutes and resolved spontaneously. He has a normal neurological examination
More informationIdentifying Patients for Anticoagulation: While Many Patients Remain Untreated, Who Should NOT be Anticoagulated?
Identifying Patients for Anticoagulation: While Many Patients Remain Untreated, Who Should NOT be Anticoagulated? Renato D. Lopes, MD MHS PhD Professor of Medicine Division of Cardiology Duke Clinical
More informationMulticenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy with HeartMate 3 (MOMENTUM 3) Long Term Outcomes
Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy with (MOMENTUM 3) Long Term Outcomes Mandeep R. Mehra, MD, Daniel J. Goldstein, MD, Nir Uriel, MD, Joseph
More informationDo Not Cite. Draft for Work Group Review.
Defect Free Acute Inpatient Ischemic Stroke Measure Bundle Measure Description Percentage of patients aged 18 years and older with a diagnosis of ischemic stroke OR transient ischemic attack who were admitted
More informationIs there a place for new anticoagulants in prosthetic valves?
Is there a place for new anticoagulants in prosthetic valves? Patrizio Lancellotti, MD, PhD, FESC, FACC University of Liège Hospital, GIGA Cardiovascular Sciences, Heart Valve Clinic, Department of Cardiology,
More informationW e have previously reported the results of a randomised
715 CARDIOVASCULAR MEDICINE Twenty year comparison of a mechanical heart valve with porcine bioprostheses H Oxenham, P Bloomfield, D J Wheatley, R J Lee, J Cunningham, R J Prescott, H C Miller... See end
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Bhakta N, Liu Q, Yeo F, et al. Cumulative burden
More informationGestione peri-operatoria del paziente in terapia con antagonisti della vitamina K. B. Cosmi
Gestione peri-operatoria del paziente in terapia con antagonisti della vitamina K B. Cosmi Department of Angiology and Blood Coagulation S. Orsola-Malpighi University Hospital Bologna, Italy Overview Background
More informationBeta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes
Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes Seung-Jae Joo and other KAMIR-NIH investigators Department of Cardiology, Jeju National
More informationLow-Molecular-Weight Heparin
Low-Molecular-Weight Heparin Policy Number: Original Effective Date: MM.04.019 10/15/2007 Line(s) of Business: Current Effective Date: HMO; PPO 10/28/2011 Section: Prescription Drugs Place(s) of Service:
More informationMechanical heart valves and Anticoagulation. Dr. Alkesh ZALA Basic Physician trainee, Dept. of Cardiology, John Hunter hospital.
Mechanical heart valves and Anticoagulation Dr. Alkesh ZALA Basic Physician trainee, Dept. of Cardiology, John Hunter hospital. Today s discussion: Case review The currently Available and most commonly
More information